Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,200,000 additional shares, … [Read more…]
